China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has announced that Denmark-based Adcendo ApS has exercised its options within a research, option, and licensing agreement to utilize Biocytogen’s fully human antibodies. This move is aimed at bolstering Adcendo’s antibody drug conjugate (ADC) pipeline.
Adcendo’s Focus on First-In-Class ADCs
Adcendo is a biotechnology company dedicated to the development of innovative first-in-class antibody-drug conjugates (ADCs) for the treatment of various cancers. By leveraging Biocytogen’s technology, Adcendo seeks to enhance its product pipeline and contribute to the advancement of cancer therapies.
Biocytogen’s RenMice Platform and Its Advantages
Biocytogen boasts its RenMice antibody discovery platform, which enables the discovery of fully human antibodies characterized by high affinity, low immunogenicity, and strong potential for development. This platform is a valuable asset in the biotechnology industry, providing a robust foundation for the creation of novel therapeutics.-Fineline Info & Tech
